Teresa J. Melink

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Marina Konopleva, Peter F. Thall, Cecilia Arana Yi et al. · Haematologica · 2015 · 122 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses

Charles H. Redfern, Troy H. Guthrie, Alberto Bessudo et al. · Journal of Clinical Oncology · 2006 · 89 citations

Medicine, Hematology, Immunology +16

Interferon-alpha therapy of renal cancer.

James A. Neidhart, Mary M. Gagen, Donn Young et al. · PubMed · 1984 · 81 citations

Medicine, Oncology, Pharmacology +15

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Mark J. McKeage, Yongchuan Gu, William R. Wilson et al. · BMC Cancer · 2011 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Mark J. McKeage, Michael B. Jameson, Ramesh K. Ramanathan et al. · BMC Cancer · 2012 · 63 citations · Full text

Medicine, Oncology, Pharmacology +15